Welcome to our dedicated page for Vistagen Therapeutics news (Ticker: VTGN), a resource for investors and traders seeking the latest updates and insights on Vistagen Therapeutics stock.
Vistagen Therapeutics, Inc. develops late clinical-stage biopharmaceutical programs based on nose-to-brain neurocircuitry and intranasal pherine product candidates. Company news centers on fasedienol nasal spray for the acute treatment of social anxiety disorder, including PALISADE Phase 3 study updates, and refisolone nasal spray for vasomotor symptoms due to menopause.
Recurring updates also cover FDA and IND communications, clinical data from psychiatric and neurological programs, fiscal results, cash-management actions, executive and board changes, and healthcare investor conference presentations. The company’s pipeline is described around investigational intranasal candidates for indications that include social anxiety disorder, major depressive disorder, and menopausal hot flashes.
VistaGen Therapeutics (NASDAQ: VTGN) has entered a strategic licensing agreement with EverInsight Therapeutics for the development and commercialization of PH94B, a novel neurosteroid for anxiety disorders, in Greater China, South Korea, and Southeast Asia. VistaGen will receive a $5 million upfront payment and potential milestone payments of up to $172 million. The collaboration aims to advance Phase 3 clinical development for PH94B, which has Fast Track designation from the FDA for social anxiety disorder. VistaGen retains rights outside this territory.